

3	Colorado* (2015) ²² "Effects of Cannabidiol [CBD] in the Treatment of Patients with Parkinson's Disease: An	24						
---	---	----	--	--	--	--	--	--

	Patients with Crohn's Disease" (2014) ⁴⁵		with Crohn's disease." ⁴⁷						
3	"Cannabis Use Amongst Patients with Inflammatory Bowel Disease" (2011) ⁴⁸	<i>European Journal of Gastroenterology & Hepatology</i> , ranked 54/79 in the "Gastroenterology and Hepatology" category in 2015. ⁴⁹	"Cannabis use is common amongst						

PTSD is a mental health disorder that people develop following a life-threatening or traumatic event. PTSD diagnoses are typically made using the

studies demonstrated a statistically significant

	Patients Evaluated for the New Mexico Cannabis Program" (2014) ⁶⁸	<i>Drugs</i> , ranked 57/122 in the "Clinical Psychology" category in 2015. ⁶⁹	supports a conclusion that cannabis is associated with PTSD symptom reduction in some patients, and a prospective, placebo-controlled study of cannabis or its constituents for treatment of PTSD is warranted." ⁷⁰						The data was collected through a retrospective chart review.
3	"Preliminary, Open-Label, Pilot Study of Add-On Oral Delta ⁹ -Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder" (2014) ⁷¹	<i>Clinical Drug Investigation</i> , ranked 165/255 in the "Pharmacology and Pharmacy" category in 2015. ⁷²	"The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms." ⁷³	Yes	None	No	No	Yes	Sample Size: 10. Duration of Study: 3 weeks.
4	"The Use of a Synthetic Cannabinoid in the Management of Treatment-Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)" (2009) ⁷⁴	<i>CNS Neuroscience & Therapeutics</i> was ranked 65/256 in the "Neurosciences" category and 43/255 in the "Pharmacology and Pharmacy" category in 2015. ⁷⁵	"A chart review of patients diagnosed with PTSD who were referred to a private psychiatric clinic suggests that the synthetic cannabinoid, nabilone, has beneficial effects beyond its	Yes	None	No	No	Yes	Sample Size: 47. This study is limited due to participants' subjective reports of changes in nightmare patterns and by selection bias in the research design.

⁶⁸ Greer et al., "PTSD Symptom Reports of Patients," 73-76.

⁶⁹ "Journal of Psychoactive Drugs," InCites Journal Citation Reports, last modified September 2, 2016, <https://jcr.incites.thomsonreuters.com/JCRJournalProfileAction.action?pg=JRNLPF&journalImpactFactor=1.775&year=2015&journalTitle=JOURNAL%20OF%20PSYCHOACTIVE%20DRUGS&edition=SSCI&journal=J%20PSYCHOACTIVE%20DRUGS>.

⁷⁰ Greer et al., "PTSD Symptom Reports of Patients," 76.

⁷¹ Roitman et al., "Preliminary, Open-Label, Pilot Study," 587-91.

⁷²

			official indication in regard to abolishing or greatly reducing nightmares that persisted in spite of treatment with conventional PTSD medications." 76						
5	"The Efficacy of Nabilone, a Synthetic Cannabinoid, in the Treatment of PTSD-Associated Nightmares: A Preliminary Randomized, Double-Blind, Placebo-Controlled Cross-Over Design Study" (2015) ⁷⁷	<i>Psychoneuroendocrinology</i> , ranked 47/256 in the "Neurosciences" category and 23/142 in the "Psychiatry" category in 2015. ⁷⁸	"NAB provided significant relief for military personnel with PTSD, indicating that it shows promise as a clinically-relevant treatment for patients with nightmares and a history of non-response to traditional therapies." 79	Yes	None	Yes	Yes	Yes	Sample Size: 10. Duration of Study: 7 weeks. The gender

